Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome: Bursa Uludag University Experience

The management of acute myeloid leukemia (AML) gradually turns into an individualized approach with the application of targeted therapies. Venetoclax is a BCL-2 inhibitor that is synergistic with azacitidine. In this case series, 14 patients diagnosed with relapsed / refractory AML and 1 MDS RAEB-1...

Full description

Bibliographic Details

Published in:	Turkish Journal of Internal Medicine
Main Authors:	İbrahim Ethem Pınar, Fahir Özkalemkaş, Vildan Ozkocaman, Ömer Candar, Tuba Ersal, Cumali Yalçın, Bedrettin Orhan
Format:	Article
Language:	English
Published:	Nizameddin KOCA 2021-03-01
Subjects:	venetoclax azacitidine acute myeloid leukemia myelodysplastic syndrome
Online Access:	https://dergipark.org.tr/tr/download/article-file/1565526